A new hope for GeNeuro

It’s only about two weeks ago when GeNeuro’s hopes for a quick win with its HERV-W human endogenous retrovirus program…

Rise of the Natural Killer Cell

In immunotherapy, a lot of research and clinical development programs have so far focused on T-cell mediated tumor killing. PD1…

Positive ARIEL-3 readout

The PARP space continues to generate positive data. Clovis Oncology just released positive rucaparib topline data in the maintenance treatment…

IgA Nephropathy Breakthrough

As previsouly indicated by Omeros’ CEO, Greg Demopulos, the FDA is keen to accelerate the development of OMS721, a human…